Viral claims of a one-time injection to eliminate high cholesterol are gaining traction online, fueled by early clinical trial results exploring the potential of CRISPR gene editing. While promising, this emerging therapy-currently focused on genes like PCSK9 and ANGPTL3-remains in the experimental phase, with researchers emphasizing the need for extensive long-term safety and efficacy studies. This article examines the science behind these trials, the limitations of current data, and the ethical considerations surrounding permanent alterations to the human genome.
A single injection with the potential for long-lasting reduction of “bad” cholesterol is generating buzz online. Behind the hype, real clinical trials are exploring CRISPR gene editing, offering therapeutic hope alongside significant ethical questions.
For months, viral posts have claimed a single injection could permanently replace a lifetime of cholesterol medication. The message is appealing – no more daily pills, no more statins, but a one-time, targeted genetic correction. However, this simplified narrative obscures a more nuanced scientific reality based on early-stage experimental work.
The technology centers around CRISPR-Cas9 gene editing, a tool that allows for precise modification of DNA. In the case of cholesterol, researchers are primarily targeting the PCSK9 gene, found in the liver. This gene plays a key role in regulating LDL cholesterol levels: when active, it limits the liver’s ability to remove LDL. For about fifteen years, scientists have known that individuals with natural mutations that inactivate PCSK9 tend to have very low LDL levels and a significantly reduced risk of cardiovascular disease.
Building on this observation, researchers first developed antibodies against PCSK9, and more recently, a more radical approach: directly disabling the gene itself. In 2023, an international team published initial results from a Phase 1 clinical trial using an in vivo CRISPR therapy called VERVE-101 in the New England Journal of Medicine. This therapy utilizes a “base editing” system – a more precise form of CRISPR – delivered via intravenous injection, specifically targeting liver cells.
Preliminary results showed LDL cholesterol reductions of up to approximately 50% in some participants after a single injection, with the effect lasting for several months. These findings sparked considerable excitement, as they are comparable to, or even better than, results achieved with statins or PCSK9 inhibitors taken regularly. However, it’s crucial to remember that these trials involved a very small number of patients with severe hypercholesterolemia and a high risk of cardiovascular events, and were primarily designed to assess the treatment’s safety, not its long-term effectiveness.
Another approach, called CTX310, targets the ANGPTL3 gene, also involved in regulating blood fats. Presented in late 2025 at the American Heart Association conferences, this experimental CRISPR-Cas9 therapy was administered once via intravenous infusion to fifteen volunteers with difficult-to-treat lipid disorders. Preliminary results showed an average LDL reduction of about 50%, and in some cases up to 70%, along with a roughly 55% decrease in triglycerides, with no serious adverse effects reported. The effects were observed as early as two weeks after treatment and were maintained for at least sixty days in available follow-up data. These data confirm the feasibility of a durable genetic correction of lipid mechanisms, but are limited by the study’s size and duration.
The viral claims, however, are misleading. Describing a “definitive replacement” for daily treatments is scientifically premature. Modifying the DNA of liver cells is, by definition, irreversible. Any irreversible therapy demands extremely high safety standards. The primary risks involve “off-target” effects – unintended modifications to DNA elsewhere in the genome, potentially leading to unforeseen consequences, including cancer. While newer generations of CRISPR are more precise, long-term clinical data remains limited. Understanding these risks is critical as gene editing technologies advance.
Furthermore, cholesterol is not a simple monogenic disease in most cases. Common hypercholesterolemia results from complex interactions between genetics, diet, lifestyle, and other metabolic conditions. Disabling PCSK9 or ANGPTL3 won’t address poor dietary habits, chronic inflammation, or other cardiovascular risk factors like smoking, hypertension, or diabetes. Gene therapy may therefore be most appropriate for highly targeted populations.
Researchers themselves are proceeding with caution. In their publications, they emphasize the need for prolonged follow-up over several years, as well as Phase 2 and 3 trials involving a much larger number of patients. Regulatory agencies, such as the FDA and EMA, are also imposing particularly strict criteria for any therapy that permanently alters the genome.
Despite the caution, the enthusiasm is understandable. If these approaches are confirmed, they could transform cardiovascular prevention for certain high-risk patients, particularly those who cannot tolerate current treatments or have severe genetic forms of the condition. More broadly, this work paves the way for preventative medicine focused on biologically correcting disease mechanisms upstream, rather than managing chronic symptoms.
However, the path from scientific promise to clinical reality remains long. At this stage, CRISPR has not replaced statins; it has simply opened the door to a future where prevention might, one day, involve gene correction rather than taking a pill. The question remains whether society will accept permanent alterations to the genome for disease prevention. This is a scientific question, but also an ethical one.
Sources
– Laffin, L.J., Nicholls, S.J. et al. CRISPR-Cas9 Gene Editing Targeting ANGPTL3: First-in-Human, Phase 1 Results. New England Journal of Medicine, 2025.
– Musunuru, K. et al. In Vivo Base Editing of PCSK9 in Humans. New England Journal of Medicine, 2023.
– Musunuru, K. et al. Base Editing for Cholesterol Reduction in Monkeys and Human Cells. Nature, 2021.
– Cohen, J.C., Boerwinkle, E., Mosley, T.H. Jr., & Hobbs, H.H. Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease. New England Journal of Medicine, 2006.
